The treatment approach for patients with estrogen receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer has changed dramatically over the past 20 years. In the past, the usual approach involved administering the available single agents (tamoxifen, aromatase inhibitors, and fulvestrant) sequentially until endocrine sensitivity was exhausted and…
The New England Journal of Medicine: Search Results in Hematology/Oncology
